Osteostatin, derived from parathyroid hormone-related protein (PTHrP) 107-111, has demonstrated properties conducive to bone repair in animal models presenting with bone defects and exhibits efficacy in mitigating bone erosion associated with inflammatory arthritis. Additionally, it possesses the capacity to inhibit both collagen-induced arthritis and direct osteoclastic bone resorption, marking its potential utility in inflammation and immunology research [1] [2] [3] [4].

Osteostatin (100、250、500 nM，7-9天) 浓度依赖性地减少了破骨细胞的分化[2]。

骨肽（每天皮下注射80或120 μg/kg，治疗从疾病发作后开始，连续13天）能显著减轻关节炎症状并抑制软骨及骨质的降解^[4]。